Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969

Global prevalence of dementia: a Delphi consensus study

Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336

Defining the clinical course of multiple sclerosis

LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065

Revising the definition of Alzheimer's disease: a new lexicon

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863

Practice parameter: Management of dementia (an evidence-based review) [RETIRED]

Doody, R. S., Stevens, J. E., Beck, C., Dubinsky, R., Kaye, J. A., Gwyther, L. P., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,708

Linking Enzyme Upregulation to Autophagic Failure: A Potential Biomarker for GM1 GangliosidosisPreprint

Smith, S. E., & Larsen, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.28.359083 · Cited by 1

The neutrophil to lymphocyte ratio associates with markers of Alzheimer’s disease pathology in cognitively unimpaired elderly peoplePreprint

Jacobs, T., Jacobson, S. R., Fortea, J., Berger, J. S., Vedvyas, A., Marsh, K., He, T., Gutiérrez‐Jiménez, E., Fillmore, N. R., Bubu, O. M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4076789/v1 · Cited by 1

Connecting genomic and proteomic signatures of amyloid burden in the brainPreprint

Puerta, R., de Rojas, I., García‐González, P., Olivé, C., Sotolongo‐Grau, Ó., García‐Sánchez, A., García‐Gutiérrez, F., Montrreal, L., Tartari, J. P., Sanabria, Á., et al. (2024) · medRxiv · doi:10.1101/2024.09.06.24313124 · Cited by 1

Biomarkers for neurological disorders – call for standardization

Torzewski, M. (2014) · Journal of Laboratory Medicine · doi:10.1515/labmed-2014-0002

The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration

Martone, R. L., Snyder, R. H., Xu, A. S. L., & Reams, R. Y. (2012) · Current Translational Geriatrics and Experimental Gerontology Reports · doi:10.1007/s13670-012-0015-4

Biomarker in der Neurologie – Standardisierung dringend erforderlich1)

Torzewski, M. (2014) · Journal of Laboratory Medicine · doi:10.1515/labmed-2013-0059

Las pruebas ecológicas en el deterioro cognitivo leve: el RBMT y la BADS

Gasol, B., & Salom, M. A. (2014)

Application of Alzheimer Biomarkers in Clinical Practice

Menéndez‐González, M. (2014) · Springer eBooks · doi:10.1007/978-3-319-07989-9_4

A bioenergética do músculo esquelético na Doença de Alzheimer

Alexandra, M., & de Castro, T. (2012) · Repository of UTAD (Universidad De Tras-os Montes e Alto Douro)

Cerebrospinal fluid β-amyloid1–42 levels in the differential diagnosis of Alzheimer’s Disease – systematic review and meta-analysis

Mo, J.-A., & Lim, J. H. (2014) · doi:10.5176/2382-607x_arp14.12

Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen

Psychiatrie, K. F. (2014)

Estandarización de aspectos preanalíticos para el estudio de biomarcadores de la enfermedad de Alzheimer en el líquido cefalorraquídeo

Gella, A., Plarrumaní, A. L., & Molinuevo, J. L. (2016) · Revista del Laboratorio Clínico · doi:10.1016/j.labcli.2016.09.002

Cerebrospinal fluid in Alzheimer's: A precious tool

Parnetti, L., & Cicognola, C. (2016) · Oncotarget · doi:10.18632/oncotarget.14157

Alzheimer's disease as a neuropathological continuum in clinical practice.

Sheardová, K., Hudeček, D., Hromková, O., Marciniak, R., & Hort, J. (2016) · Neurologie pro praxi · doi:10.36290/neu.2016.063

The soluble transcobalamin receptor (sCD320) in relation to Alzheimer’s disease and cognitive scores

Abuyaman, O., Combrinck, M. I., Smith, A. D., & Nexø, E. (2017) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2017.1323345

Biomarkers in dementia with Lewy bodies

Donaghy, P. C. (2016)

Featured Articles The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L. S., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Pontecorvo, M. J., Rowe, C. C., et al. (2015)

Featured Article Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial

Kim, H. J., Seo, S. W., Chang, J. W., Lee, J. I., Kim, C. H., Chin, J., Choi, S. J., Kwon, H., Yun, H. J., Lee, J. M., et al. (2015)

Proteomic-based Signature of Brain-related Proteins as Novel Candidate Biomarkers for Alzheimer’s Disease Diagnosis

Begcevic, I. (2018) · TSpace (University of Toronto)

The postsynaptic protein neurogranin: a new item in the Alzheimer’s disease biomarker toolbox

Kvartsberg, H. (2019) · Gothenburg University Publications Electronic Archive (Gothenburg University)

Detection of novel serological biomarkers in two neurodegenerative disorders

Georgieva, Y. (2014) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-11225

Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer

Cinquanta, L., & Brusca, I. (2019) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.19.00028-8

Współczesna diagnostyka laboratoryjna choroby Alzheimera

Beck, B., & Siudek, B. (2019)

Effects of various pre-analytical conditions on blood-based biomarkers of Alzheimer’s disease

Ladang, A., Rigaud, L., Sqalli, G., & Cavalier, E. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0637

Комплексный метод анализа геометрической точности цилиндров в процессе сборки судовых малоразмерных дизелей

Яхьяевич, Я. Н., & Vagabov, N. M. (2009) · VESTNIK OF ASTRAKHAN STATE TECHNICAL UNIVERSITY SERIES MARINE ENGINEERING AND TECHNOLOGIES

Pre-Analytical Errors in Clinical Diagnostic Laboratory: A Crucial Step to Look for Accuracy and Reliability

Shah, T. (2021) · Indian Journal of Forensic Medicine & Toxicology · doi:10.37506/ijfmt.v15i1.13690v

Einfluss von prä-analytischen Entnahme- und Lagerungsbedingungen auf die Stabilität und Konzentration von Amyloid-ß-Peptiden in Blut

Walter, M. (2022) · doi:10.53846/goediss-9330

Lumbar Puncture Increases Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid of Rhesus MonkeysPreprint

Xu, J., Li, H., Hu, Y., Wu, S., Wu, L., Lv, L., Lu, Y., Wu, J., Li, J., Shi, B., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4520972

Alzheimer’s Disease and Other Neurodegenerative Dementias

Sancesario, G. M., & Bernardini, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-24958-7_39

Diagnosis of Alzheimer's disease and other neurodegenerative diseases using cerebrospinal fluid and blood-based biomarkers

Vyhnálek, M., & Veverová, K. (2024) · Neurologie pro praxi · doi:10.36290/neu.2023.065

Neurons as biosensors for discriminating neurological disorders in a brain-on-chip platform: Application to Alzheimer’s Disease using patient CSFPreprint

Miny, L., Rontard, J., Allouche, A., Violle, N., Dubuisson, L., Batut, A., Ponomarenko, A., Talbi, R., Gautier, H. O. B., Maisonneuve, B. G. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.23.609425

Long-read sequencing reveals two common APOE ε3 and ε4 intragenic haplotypes in the Spanish populationPreprint

García‐González, P., Puerta, R., Muñoz-Morales, Á., Olivé, C., Calm, B., Montrreal, L., Valenzuela, A., Bayón-Buján, P., Rovira, M., Capdevila-Bayo, M., et al. (2025) · medRxiv · doi:10.1101/2025.03.25.25324541

Recommendation to analysis of cerebrospinal fluid

Mrázová, K., Zeman, D., Bořecká, K., Zenkova, J., Brož, P., Mareš, J., Hanzalová, J., Král, V., & Krbková, L. (2017) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2017.008

Impact of Pre-analytical Factors on Fluid Biomarker Measurements in Alzheimer Disease

Torres‐Torronteras, J., Gouda, M., Teunissen, C. E., Verberk, I. M. W., & del Campo, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_16

Additional file 5 of Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey-Smith, S. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12057588

Additional file 1 of Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey-Smith, S. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12057564

Additional file 1 of Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status

Reas, E. T., Triebswetter, C., Banks, S. J., & McEvoy, L. K. (2024) · Figshare · doi:10.6084/m9.figshare.24987857

Additional file 1 of Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease

Ahmad, S., Orellana, A., Kohler, I., Frölich, L., de Rojas, I., Gil, S., Boada, M., Hernández, I., Hausner, L., Bakker, M. H. M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047107

Additional file 6 of Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey-Smith, S. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12057597

Additional file 1 of Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Verberk, I. M. W., Thijssen, E. H., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13018138

Additional file 1 of Mild behavioral impairment in early Alzheimer’s disease and its association with APOE and BDNF risk genetic polymorphisms

Matušková, V., Veverová, K., Jester, D. J., Maťoška, V., Ismail, Z., Sheardová, K., Horáková, H., Cerman, J., Laczó, J., Andel, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25092515

Additional file 1 of Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

Cano, A., Antonio, E. E., Bernuz, M., Puerta, R., García‐González, P., de Rojas, I., Olivé, C., Pérez‐Cordón, A., Montrreal, L., Núñez‐Llaves, R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22607779

Additional file 1 of Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment

Ahmad, S., Yang, W., Orellana, A., Frölich, L., de Rojas, I., Cano, A., Boada, M., Hernández, I., Hausner, L., Harms, A. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26755654

Additional file 1 of Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers

Wang, J., Fan, D.-Y., Li, H.-Y., He, C.-Y., Shen, Y.-Y., Zeng, G.-H., Chen, D.-W., Yi, X., Ma, Y.-H., Yu, J.-T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.18482235

Additional file 3 of Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey-Smith, S. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12057576

Additional file 1 of The neutrophil to lymphocyte ratio associates with markers of Alzheimer’s disease pathology in cognitively unimpaired elderly people

Jacobs, T., Jacobson, S. R., Fortea, J., Berger, J. S., Vedvyas, A., Marsh, K., He, T., Gutiérrez‐Jiménez, E., Fillmore, N. R., Gonzalez, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25853015

Additional file 4 of Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey-Smith, S. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12057582

Additional file 1 of Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?

Bellomo, G., Cataldi, S., Paciotti, S., Paolini Paoletti, F., Chiasserini, D., & Parnetti, L. (2020) · Figshare · doi:10.6084/m9.figshare.13023822

Additional file 1 of Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

Doecke, J. D., François, C., Fowler, C. J., Stoops, E., Bourgeat, P., Rainey-Smith, S. R., Li, Q.-X., Masters, C. L., Martins, R. N., Villemagne, V. L., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14442834

Additional file 2 of Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey-Smith, S. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12057570

Additional file 7 of Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey-Smith, S. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12057600

Additional file 2 of Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment

Ahmad, S., Yang, W., Orellana, A., Frölich, L., de Rojas, I., Cano, A., Boada, M., Hernández, I., Hausner, L., Harms, A. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26755657

Additional file 1 of Arterial stiffening acts synergistically with APOE genotype and AD biomarker status to influence memory in older adults without dementia

Bangen, K. J., Smirnov, D. S., Delano‐Wood, L., Wierenga, C. E., Bondi, M. W., Salmon, D. P., & Galasko, D. (2021) · Figshare · doi:10.6084/m9.figshare.14897177

Développement d’outils pour la caractérisation de la TDP-43 et exploration de marqueurs indirects dans un contexte de dégénérescence lobaire frontotemporale

Escal, J. (2021) · theses.fr (ABES) · doi:10.70675/c8b346f7zb4e3z43e0za63azb407baddab64

Listening for Alzheimer’s clues: machine learning analysis of multidomain speech features for cognitive impairment screening

Blázquez-Folch, J., Calm, B., Hinojosa-Calleja, A., García‐Gutiérrez, F., Alegret, M., Muñoz, N., Cano, A. C., Fernández, M. V., Miguel, A., Solivar, A., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1816747 · Cited by 2

A peripheral proteomic signature of Alzheimer’s disease is identified in the plasma extracellular vesicles of mild cognitive impairment patients from a memory clinic: the BIOPEXAL study

Capdevila-Bayo, M., Rossi, R., de Rojas, I., Puerta, R., Guzman, L., Carrasco, M., Muñoz-Morales, Á., Olivé, C., Montrreal, L., García‐González, P., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04952-8 · Cited by 1

Alzheimer's Co‐Pathology Burden on Basal Forebrain Atrophy and Cognitive Impairment in Dementia with Lewy Bodies: A Cross‐Sectional Pilot Study

Urso, D., Giannelli, T., Tafuri, B., Giannoni‐Luza, S., Gnoni, V., Giugno, A., Vilella, D., Zecca, C., Blasi, R. D., Nigro, S., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78357

Age-Stratified Serum Biomarkers for Discriminating Clinically Defined Cognitive Impairment in Neurological Inpatients: A Cross-Sectional Study

Gu, D., Lei, Y., Lu, J., Yi, W., Zhang, Q., He, Y., Wang, C., & 蔡志友 (2026) · Brain Sciences · doi:10.3390/brainsci16101080

The IFCC-Siemens Specialized Conference

Booth, R. A., & Bernardini, S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.06.018

A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease

Park, S. A., Kang, J.-H., Kang, E., Ki, C., Roh, J. H., Youn, Y. C., Kim, S. Y., & Kim, S. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.2.132 · Cited by 19

of the Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

(2016)

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Hansson, O., Mikulskis, A., Fagan, A. M., Teunissen, C. E., Zetterberg, H., Vanderstichele, H., Molinuevo, J. L., Shaw, L. M. J., Vandijck, M. L. J., Verbeek, M. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.008 · Cited by 123

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability

Fourier, A., Portelius, E., Zetterberg, H., Blennow, K., Quadrio, I., & Perret‐Liaudet, A. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.05.024 · Cited by 94